Yeasmin S - Search Results

1

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. Nakayama N, et al. Among authors: yeasmin s. Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18. Br J Cancer. 2008. PMID: 19018267 Free PMC article.

2

Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.

Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida K, Maruyama R, Fukumoto M, Miyazaki K. Huan Z, et al. Among authors: yeasmin s. Oncol Rep. 2008 Mar;19(3):775-81. Oncol Rep. 2008. PMID: 18288415

3

Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.

Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N, Miyazaki K. Yeasmin S, et al. Clin Cancer Res. 2008 Mar 15;14(6):1686-91. doi: 10.1158/1078-0432.CCR-07-4085. Clin Cancer Res. 2008. PMID: 18347169

4

A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K. Ishibashi M, et al. Among authors: yeasmin s. Clin Cancer Res. 2008 May 15;14(10):3149-55. doi: 10.1158/1078-0432.CCR-07-4358. Clin Cancer Res. 2008. PMID: 18483383

5

Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K. Yeasmin S, et al. Int J Cancer. 2011 Jan 1;128(1):94-104. doi: 10.1002/ijc.25332. Int J Cancer. 2011. PMID: 20309881

6

Biological role and prognostic significance of NAC1 in ovarian cancer.

Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K. Nakayama K, et al. Among authors: yeasmin s. Gynecol Oncol. 2010 Dec;119(3):469-78. doi: 10.1016/j.ygyno.2010.08.031. Epub 2010 Sep 24. Gynecol Oncol. 2010. PMID: 20869761

7

MKK4 acts as a potential tumor suppressor in ovarian cancer.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K. Yeasmin S, et al. Tumour Biol. 2011 Aug;32(4):661-70. doi: 10.1007/s13277-011-0166-5. Epub 2011 Apr 14. Tumour Biol. 2011. PMID: 21487811

8

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K. Iida K, et al. Among authors: yeasmin s. Br J Cancer. 2011 Jul 26;105(3):420-7. doi: 10.1038/bjc.2011.222. Epub 2011 Jul 5. Br J Cancer. 2011. PMID: 21730982 Free PMC article.

9

Expression of a BTB/POZ protein, NAC1, is essential for the proliferation of normal cyclic endometrial glandular cells and is up-regulated by estrogen.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K. Ishibashi M, et al. Among authors: yeasmin s. Clin Cancer Res. 2009 Feb 1;15(3):804-11. doi: 10.1158/1078-0432.CCR-08-2134. Clin Cancer Res. 2009. PMID: 19188150

10

[A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy].

Ishibashi M, Nakayama K, Oride A, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K. Ishibashi M, et al. Among authors: yeasmin s. Gan To Kagaku Ryoho. 2009 Mar;36(3):513-7. Gan To Kagaku Ryoho. 2009. PMID: 19295284 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters